Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) – Research analysts at Wedbush lowered their Q3 2019 earnings per share estimates for shares of Lexicon Pharmaceuticals in a research note issued to investors on Monday, March 25th. Wedbush analyst L. Moussatos now anticipates that the biopharmaceutical company will earn ($0.25) per share for the quarter, down from their previous estimate of ($0.23). Wedbush has a “Outperform” rating and a $38.00 price target on the stock. Wedbush also issued estimates for Lexicon Pharmaceuticals’ Q4 2019 earnings at ($0.30) EPS, FY2019 earnings at ($0.95) EPS, FY2020 earnings at ($1.60) EPS, FY2021 earnings at ($0.31) EPS, FY2022 earnings at $1.00 EPS and FY2023 earnings at $2.02 EPS.

A number of other research firms have also recently weighed in on LXRX. Gabelli cut Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, March 13th. BidaskClub upgraded Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, March 14th. Zacks Investment Research cut Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, January 18th. ValuEngine upgraded Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, March 12th. Finally, Stifel Nicolaus decreased their price target on Lexicon Pharmaceuticals from $14.00 to $10.00 and set a “buy” rating for the company in a report on Monday. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $17.13.

NASDAQ LXRX opened at $5.26 on Wednesday. The company has a market capitalization of $574.93 million, a price-to-earnings ratio of -4.61 and a beta of 0.70. Lexicon Pharmaceuticals has a fifty-two week low of $4.25 and a fifty-two week high of $13.97.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its quarterly earnings results on Wednesday, March 13th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.28) by $0.12. The firm had revenue of $17.10 million during the quarter, compared to analysts’ expectations of $13.33 million. Lexicon Pharmaceuticals had a negative return on equity of 911.43% and a negative net margin of 192.53%. Lexicon Pharmaceuticals’s quarterly revenue was down 49.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.27) EPS.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Pegasus Asset Management Inc. purchased a new position in shares of Lexicon Pharmaceuticals during the 4th quarter valued at approximately $66,000. Paloma Partners Management Co purchased a new position in shares of Lexicon Pharmaceuticals during the 4th quarter valued at approximately $73,000. CWM Advisors LLC boosted its stake in shares of Lexicon Pharmaceuticals by 30.2% during the 4th quarter. CWM Advisors LLC now owns 13,059 shares of the biopharmaceutical company’s stock valued at $87,000 after buying an additional 3,030 shares during the last quarter. D.A. Davidson & CO. purchased a new position in shares of Lexicon Pharmaceuticals during the 4th quarter valued at approximately $87,000. Finally, Metropolitan Life Insurance Co. NY boosted its stake in shares of Lexicon Pharmaceuticals by 409.3% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 14,760 shares of the biopharmaceutical company’s stock valued at $98,000 after buying an additional 11,862 shares during the last quarter. Hedge funds and other institutional investors own 99.16% of the company’s stock.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

Featured Article: Is it Safe to Invest in Commodities?

Earnings History and Estimates for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.